Skip to main content

Advertisement

Table 3 Plasma EBV DNA levels in the 93 patients with detectable EBV DNA during posttreatment follow-up

From: Prognostic value of plasma Epstein–Barr virus DNA level during posttreatment follow-up in the patients with nasopharyngeal carcinoma having undergone intensity-modulated radiotherapy

Emergence of plasma EBV DNA during posttreatment follow-up Disease free Tumor recurrence P d
No. of patients 40 53 NA
Before clinical detectiona [n (%)] NA 29 (54.7) NA
Transiently detectableb [n (%)] 39 (97.5) 5 (9.4) < 0.001
Plasma EBV DNA levelc [copies/mL; median (range)] 805 (30–8840) 3940 (40–2,420,000) NA
EBV DNAc > 500 copies/mL [n (%)] 24 (60.0) 42 (79.2) 0.043
EBV DNAc > 1000 copies/mL [n (%)] 16 (40.0) 37 (69.8) 0.004
  1. NA not applicable
  2. a Emergence of plasma EBV DNA during posttreatment follow-up before clinical detection of recurrence
  3. bPlasma EBV DNA was transiently detected followed by a rapid regression to be undetectable
  4. cThe emergence level of EBV DNA during posttreatment follow-up period
  5. d P values were calculated using the χ² test